Medical Oncology

, Volume 19, Issue 1, pp 69–72 | Cite as

Long-standing resolution of anemia in symptomatic low-grade non-hodgkin’s lymphoma patients treated with recombinant human erythropoietin as sole therapy

Case Report
  • 33 Downloads

Abstract

Anemia is a predominant clinical problem in the management of patients with non-Hodgkin’s lymphoma and often an indication to initiate chemotherapy. However, many elderly patients, especially those with concomitant disorders, do not tolerate such therapy very well. This report describes three patients with low-grade non-Hodgkin’s lymphoma who were treated solely with recombinant human erythropoietin (rhEPO) for lymphoma-associated anemia. The rhEPO was given at an initial dose of 150 U/kg three times weekly, with dose reduction when a response had been achieved. All three patients normalized their hemoglobin level and severe anemia-related symptoms disappeared. Responses are ongoing in two patients after 10 and 12 mo of therapy, respectively. The third patient maintained a response to rhEPO for over 5 yr, without any need for further therapeutic interventions, before dying of an unrelated event. This treatment strategy seems worthy of further investigation in selected lymphoma patients where anemia is the major complication of the disease.

Key Words

Anemia chronic lymphocytic leukemia erythropoietin large granular lymphocytic leukemia non-Hodgkin’s lymphoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Moullet, I., et al. (1998). Frequency and significance of anemia in non-Hodgkin’s lymphoma patients. Ann. Oncol. 9:1109–1015.PubMedCrossRefGoogle Scholar
  2. 2.
    Cazzola, M., et al. (1995). Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of predictors of response. Blood 86:4446–4453.PubMedGoogle Scholar
  3. 3.
    Österborg, A., et al. (1996). Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma — a randomized multicenter study. The European study group of erythropietin (Epoetin beta) treatment in multiple myeloma and non-Hodgkin’s lymphoma. Blood 87:2675–2682.PubMedGoogle Scholar
  4. 4.
    Österborg A. (2000). The role of recombinant human erythropoetin in the management of anaemic cancer patients: focus on haematological malignancies. Med. Oncol. 17 (Suppl. 1):S17-S22.Google Scholar
  5. 5.
    Cazzola M. (2000). Mechanisms of anaemia in patient’s with malignancy: implications for the clinical use of recombinant human erythropoietin. Med. Oncol. 17 (Suppl. 1):S11-S16.PubMedGoogle Scholar
  6. 6.
    Siakantaris, M.P., et al. (2000). Correction of disease related anaemia of B-chronic lymphoproliferative disorders by recombinant human erythropoietin: maintenance is necessary to sustain response. Leuk. Lymphoma 40:141–147.PubMedCrossRefGoogle Scholar
  7. 7.
    Lamy, T. and Laughran, T.P., Jr. (1998). Large granular lymphocyte leukemia. Cancer Control 5:25–33.PubMedGoogle Scholar

Copyright information

© Humana Press Inc 2002

Authors and Affiliations

  1. 1.Department of MedicineStockholm Southern HospitalStockholmSweden

Personalised recommendations